Cann Group (ASX:CAN) has announced preliminary results from their Phase 3 clinical trial comparing the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances.

The trial included 257 participants and showed no statistically superior response compared to placebo.

Cann Group will evaluate the full data set and review its approach for this indication before submitting the registration application to the Therapeutic Goods Administration (TGA).

Cann Group is a company that develops, produces, and supplies innovative cannabis medicines in Australia and around the world.